Cardiac physiology

BioCardia Reports 2020 Financial Results and Recent Business Highlights

Retrieved on: 
Tuesday, March 30, 2021
Anatomy, Branches of biology, Cardiology, Heart failure, Cardiac physiology

SAN CARLOS, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular and pulmonary regenerative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2020 and recent business highlights.

Key Points: 
  • SAN CARLOS, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a leader in the development of comprehensive solutions for cardiovascular and pulmonary regenerative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2020 and recent business highlights.
  • Peer reviewed initial data from the ongoing pivotal Phase III Clinical Trial was in press in the International Journal of Cardiology in October 2020.
  • Results showed improvements at one-year follow-up in heart failure patients measured by exercise outcomes and cardiac function.
  • The Company entered into an agreement with a leading Japanese pharmaceutical company related to BioCardia Helix catheter biotherapeutic delivery product candidates.

DGAP-News: 4TEEN4's first-in-class therapeutic antibody Procizumab restores heart function in life-threatening cardiac depression induced by sepsis

Retrieved on: 
Wednesday, September 16, 2020
Cardiovascular physiology, Circulatory system, Anatomy, Branches of biology, Cardiac output, Cardiac physiology, Stroke volume

The study data (1) from the team lead by Prof. Alexandre Mebazaa have shown that high DPP3 blood values are associated with decreased heart function in a preclinical sepsis model.

Key Points: 
  • The study data (1) from the team lead by Prof. Alexandre Mebazaa have shown that high DPP3 blood values are associated with decreased heart function in a preclinical sepsis model.
  • In this randomized, controlled study, the administration of Procizumab immediately and significantly improved heart function by increasing cardiac output, stroke volume, and left ventricular shortening fraction.
  • By inhibiting DPP3 with our antibody Procizumab, we are able to restore cardiac function in preclinical sepsis models.
  • This inactivation leads to cardiac depression and consequently hemodynamic instability and consequently cardiac depression.

The antihypertensive drugs market will register a CAGR of over 2% by 2023

Retrieved on: 
Tuesday, March 19, 2019
Circulatory system, Cardiovascular physiology, Branches of biology, Cardiovascular system, Antihypertensive agents, Cardiac output, Blood pressure, Myocardial contractility, Antihypertensive drug, Cardiac physiology, Hypertension

Cardioinhibitory drugs depress cardiac function by decreasing heart rate, myocardial contractility, or both, which decreases cardiac output and arterial pressure.

Key Points: 
  • Cardioinhibitory drugs depress cardiac function by decreasing heart rate, myocardial contractility, or both, which decreases cardiac output and arterial pressure.
  • Analysts have predicted that the antihypertensive drugs market will register a CAGR of over 2% by 2023.
  • This, in turn, is expected to aid in the use of available drugs, which will drive the growth of the global antihypertensive drugs market during the forecast period.
  • For the detailed list of factors that will drive and challenge the growth of the antihypertensive drugs market during the 2019-2023, view our report.